logo_ProQR-150x150.png
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
March 24, 2021 07:00 ET | ProQR Therapeutics N.V.
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)QR-421a observed to be well...
logo_ProQR-150x150.png
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
March 17, 2021 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
February 16, 2021 16:30 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
logo_ProQR-150x150.png
ProQR Announces Expert Perspectives Conference Call Series
June 12, 2020 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
March 31, 2020 06:00 ET | ProQR Therapeutics N.V.
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse...
logo_ProQR-150x150.png
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
March 25, 2020 16:15 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
logo_ProQR-150x150.png
ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
February 26, 2020 07:00 ET | ProQR Therapeutics N.V.
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal...
34945.jpg
ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
July 02, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
34945.jpg
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
March 11, 2019 08:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
34945.jpg
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
January 29, 2019 08:30 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...